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ABSTRACT 23 
 24 
Previously, we demonstrated that frequencies of CpG and UpA dinucleotides profoundly influence 25 
the replication ability of echovirus 7 (Tulloch et al., 2014). Here, we show that that influenza A virus 26 
(IAV) with maximised frequencies of these dinucleotides in segment 5 showed comparable 27 
attenuation in cell culture compared to unmodified virus and a permuted control (CDLR). 28 
Attenuation was also manifested in vivo, with 10-100 fold reduced viral loads in lungs of mice 29 
infected with 200PFU of CpG-high and UpA-high mutants. However, both induced powerful 30 
inflammatory cytokine and adaptive (T cell and neutralising antibody) responses disproportionate to 31 
their replication. CpG-high infected mice also showed markedly reduced clinical severity, minimal 32 
weight loss and reduced immmunopathology in lung, yet sterilising immunity to lethal dose WT 33 
challenge was achieved after low dose (20PFU) pre-immunisation with this mutant. Increasing CpG 34 
dinucleotide frequencies represents a generic and potentially highly effective method for generating 35 
safe, highly immunoreactive vaccines.    36 
 37 
Builds upon: 38 
Tulloch F, Atkinson NJ, Evans DJ, Ryan MD, Simmonds P. RNA virus attenuation by codon pair 39 
deoptimisation is an artefact of increases in CpG/UpA dinucleotide frequencies. eLife 2014; 40 
3:e04531. 41 
 42 
eLife 2014;3:e04531  43 
DOI: http://dx.doi.org/10.7554/eLife.04531 44 
 45 
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IMPACT STATEMENT 47 
 48 
Mutants of influenza A virus (IAV) with increased CpG dinucleotide frequencies show restricted 49 
replication and reduced or absent pathogenicity, and powerful host innate and adaptive responses 50 
to infection that confer immunity to re-infection.  51 
 52 
 53 
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INTRODUCTION 60 
  61 
The newly developed DNA technology to create viruses (1), bacteria (2) and recently, whole 62 
eukaryotic chromosomes (3) with entirely synthetic genomes provides unparalleled opportunities to 63 
functionally explore replication and gene regulation. Insertion of sequences with large scale 64 
compositional changes using reverse genetic systems established for many RNA and DNA viruses has 65 
provided the opportunity to investigate the effect of virus genome composition on replication 66 
ability, evolutionary fitness and transmissibility. Large scale recoding of RNA virus genomes can be 67 
functionally exploited, for example to attenuate replication in a controllable way so as to create 68 
safer, non-reverting viral vaccines. Attenuation may be achieved by increasing the relative 69 
frequencies of disfavoured or rare codons encoding the same amino acid (4-6). Based on prokaryotic 70 
models, these impair translation rates and accuracy through mismatches with tRNA abundances and 71 
effects on ribosomal processivity (7). Production of synthetic coding sequences with increasing 72 
frequencies of codon pairs that are naturally under-represented in vertebrate and viral genomes 73 
have been similarly proposed to reduce translation efficiency (8-15).  74 
 75 
Current methods for virus attenuation have concentrated on sequence alterations designed to 76 
influence translation rates. However, it is increasingly recognised that both codon and codon pair 77 
de-optimisation (CPD) strategies have additional confounding effects on virus genome composition 78 
that are known to also influence virus replication (16-18). Significantly, selection for disfavoured 79 
coding elements increases frequencies of CpG and UpA dinucleotides that are normally suppressed 80 
in vertebrate RNA and DNA virus genomes. For RNA viruses, adding CpG and UpA dinucleotides in 81 
only a small part of a viral genome severely restricts virus replication, an effect that we have 82 
demonstrated to be independent of translation effects on the virus (17). The mechanism(s) through 83 
which dinucleotide composition influences virus replication rates are uncharacterised, and existing 84 
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data indicates that they are independent of interferon pathways and PKR-mediated recognition of 85 
viral RNA (16).  86 
 87 
In the current study, we have investigated whether the enhanced reactivity of cells to virus infection 88 
with high CpG/UpA frequencies in cell culture also modulates their replication and host immune 89 
responses in vivo. As an experimental model, we chose to use the A/Puerto Rico/8/34 (PR8) strain of 90 
influenza A virus (IAV) for which a reverse genetics system has been developed (19) and which 91 
replicates in a variety of cell lines and causes pathogenic infections in immunocompetent mice. This 92 
system additionally provided the opportunity to investigate whether CpG or UpA elevation showed 93 
comparable phenotypic effects on a virus with a substantially different replication mechanism to 94 
echovirus 7 (E7), which is markedly attenuated upon increase of the CpG or UpA dinucleotide 95 
frequency of its genome (16).     96 
 97 
 98 
RESULTS 99 
 100 
Generation of IAV mutants with maximised CpG and UpA dinucleotide composition. Segment 5 101 
was selected for mutagenesis as it showed no evidence for alternative reading frames, manifested 102 
by an absence of suppressed synonymous site variability (Fig. 1; Figure Supplement 1A) apart from 103 
the extreme 3’end of the gene, likely reflecting the presence of a segment-specific RNA packaging 104 
signal (20, 21).  105 
 106 
Segment 5 showed marked suppression of CpG and UpA frequencies across the segment (Fig. 1, 107 
Figure Supplement 1B), with averaged values over a window size of 120 bases consistently below the 108 
expected frequency of 0.054 based on mononucleotide composition (freq. G * freq. C). The mean 109 
observed CpG frequency of 0.026 collectively for viruses infecting human swine or avian hosts was 110 
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46% of the expected value (O/E ratio). UpA frequencies were similarly suppressed, with a mean 111 
observed frequency of 0.031 compared to an expected value of 0.068 (O/E ratio: 0.46).  112 
 113 
The program Sequence Mutate in the SSE package (22) was used to modify CpG and UpA 114 
frequencies in segment 5 without altering protein coding whilst using a recently developed option to 115 
maintain mononucleotide composition through the introduction of compensatory substitutions 116 
elsewhere in the sequence. Increases in UpA frequencies in sequences maximised for CpG content 117 
were re-normalised for UpA composition, and vice versa. Mutagenesis was carried out between 118 
positions 151-1413 of segment 5 to avoid any possible disruption of packaging signals or replication / 119 
translation elements at the terminal 150 bases at the ends of the segment (20, 21, 23).   120 
 121 
The resulting CpG-high mutant contained 86 additional CpG dinucleotides, but only one extra UpA 122 
and an identical G+C and mononucleotide content to WT virus (Table 1). The UpA-high mutant 123 
contained an additional 73 UpA dinucleotides, and was similarly normalised for CpG and 124 
mononucleotide composition. A permuted mutant (CDLR) with identical coding and dinucleotide 125 
frequencies to WT virus was generated as described previously (16). Mutants showed minimal 126 
changes (CDLR, CpG-high) or modest reductions (UpA-high) in codon pair scores.   127 
 128 
Replication phenotypes of segment 5 CpG- and UpA-high mutants. Virus stocks with WT, CDLR, 129 
CpG-high and UpA-high segment 5 sequences were produced by transfection of 293T cells with 130 
pDUAL plasmids and amplified and titrated for infectivity in MDCK cells and virions quantified by 131 
haemagglutination (HA) assay. CpG-high and UpA-high mutants showed slower replication kinetics in  132 
multistep replication assays in MDCK cells (Fig. 1A), with approximately 10-fold less infectious virus 133 
produced at the 24 hour time point. Titering of multiple replicates (n = 5) at 24 h p.i. in replicate 134 
experiments demonstrated significant differences in titre between WT and both CpG- and UpA-high 135 
mutants (p = 0.009 and p = 0.14 respectively; Fig. 1B), while replication of WT and CDLR was 136 
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equivalent (p ≈ 0.5). Similar magnitude replication deficits of the CpG and UpA mutants were also 137 
seen in single cycle infections in MDCK cells (Fig. 1; Figure supplement 2) 138 
 139 
Additional evidence for an impaired replication ability of these mutants was obtained by the 140 
observation of consistently smaller plaque sizes of CpG-high (0.061 ± 0.006 cm) and UpA-high (0.039 141 
± 0.003 cm) mutants than WT or permuted virus (0.144 ± 0.011 cm and 0.132 ± 0.010 cm 142 
respectively; Fig. 1C). Virions of CpG- and UpA-high IV mutants showed reduced infectivity compared 143 
to WT (and CDLR) variants, with approximately 3-4-fold elevated haemagglutinin (HA) to infectivity 144 
ratios in virus stocks grown in embryonated eggs (Fig. 1D). Comparable differences between WT and 145 
mutant forms of IAV were observed for RNA / infectivity ratios using a quantitative PCR (qPCR) for 146 
segment 5 sequences (Fig. 1E).  147 
 148 
To investigate whether differences in virion / infectivity ratios in IAV variants with compositionally 149 
altered segment 5 sequences were the result of packaging defect on the mutant segment, we 150 
infected MDCK cells at low MOI with WT, CDLR, CpG- and UpA-high mutants of IAV and compared 151 
frequencies of cells expressing individual proteins by immunocytochemistry at 6 hours post infection 152 
(Fig. 1; Figure supplement 3). The relative frequency of WT-infected cells expressing NP (encoded by 153 
segment 5) to those expressing viral proteins M2, NS1, NA and PB2 were comparable to those of 154 
CDLR, CpG-high and UpA-high mutants. Similarly, polyacrylaminde gel electrophoresis (PAGE) of 155 
purified egg-derived virions of WT and mutant strains revealed similar relative proportions of IAV 156 
structural proteins (Fig. 1; Figure Supplement 4). Finally, the relative amounts of segment 5 and 157 
segment 2 RNA was compared in purified virions was quantified by qPCR (Fig. 1; Figure Supplement 158 
5). RNA ratios in WT were comparable in other IAV variants. Combined, these three methods of 159 
analysis provided no evidence for a packaging defect of segment 5 in CpG- and UpA-high virions and 160 
do not explain the reduced infectivity and replication kinetics of CpG- and UpA-variants of IAV.   161 
 162 
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Replication differences between WT and mutant IAV viruses were closely reproduced in virus 163 
competition assays, in which equal infectivities of WT virus and mutant viruses were co-cultured 164 
over 5 – 10 high multiplicity passages (Fig. 1; Figure Supplement 6). Cleavage of sequences amplified 165 
from segment 5 with restriction enzymes that differentiated between mutants (Table 3) was 166 
followed by gel electrophoresis and densitometry to quantify viral populations. WT and permuted 167 
viruses fully outcompeted CpG-high and UpA-high mutants by passage 5 while UpA-high and CpG-168 
high mutants were equally fit (equimolar by passage 10) while WT showed marginally greater fitness 169 
than CDLR (WT: 60%; CDLR: 40% at passage 10). The overall fitness ranking inferred from 170 
competition assays was PR8-WT ≥ Permuted >> UpA-high = CpG-high. 171 
 172 
Overall, the in vitro findings revealed that elevation of either CpG or UpA frequencies in one 173 
segment of IAV substantially reduced replication fitness. The tenfold reductions in replication titres 174 
in the growth curve in mutants with approximately 10% genome replacement (Fig. 1A, 1B) were 175 
broadly consistent with fitness reductions associated with CpG and UpA frequency increases in E7 176 
(16) and (via codon pair de-optimisation) in IAV (24) and poliovirus (25).  177 
 178 
In vivo clinical course of IAV mutants with increased CpG and UpA frequencies in vivo. Induction of 179 
disease in mice infected with WT IAV and variants with altered dinucleotide frequencies was 180 
investigated by infection of immunocompetent 8 week old female BALB/c mice. Intranasal 181 
inoculation of groups of 6 mice with 200 PFU of WT PR8 and CDLR permuted mutant induced rapid 182 
weight loss (down to 86.3% of starting weight, standard error ± 3.2% and 86.5% ± 1.5%) by day 5 (Fig. 183 
2A). Mice showed increasing clinical signs including reduced activity, loss of condition (staring coat), 184 
increased respiration and hunching over the observation period. Mouse cohorts infected with UpA-185 
high and CpG-high mutants showed reduced weight loss (92.3% ± 2.0% and 96.4% ± 2.7% of starting 186 
weight respectively) and reduced (UpA-high) or absent (CpG-high) clinical signs compared to WT-187 
infected mice.  188 
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 189 
Although WT-infected and CDLR infected mice showed rapid weight loss, those infected with UpA- 190 
and particularly CpG-high IAV mutants showed a less severe clinical course. To investigate potential 191 
differences in recovery rates between WT and mutants and to examine virus replication and host 192 
response at different time points, three cohorts of 6 mice were inoculated each with WT, CDLR, CpG- 193 
and UpA-high variants of IAV and culled at days 3, 6 and 14 (Experiment 2; Fig 2B). Initial weight loss 194 
and clinical severity over the first 5 days was reproducible from the previous experiment with again 195 
CpG-high infected mice both strikingly reduced weight loss compared to WT and CDLR controls.  196 
Over the period after 5 days, individual mice from the WT, CDLR and UpA-high which showed >20% 197 
weight loss and more severe clinical signs and were culled. The remainder, along with all CpG-high 198 
infected mice regained weight from a nadir at around day 7-8; the latter group regained weight 199 
similar to those of the mock infected group while remaining mice retained a weight deficit through 200 
to day 14. In contrast to WT, CDLR and UpA-high infected mice, all mice infected with the CpG-high 201 
mutant remained clinically normal throughout the infection period and showed minimal weight loss 202 
over the infection period (maximum loss to 95.8% of starting weight, SE ± 1.5%).    203 
 204 
IAV virus replication in vivo. To investigate the extent of IAV replication in the respiratory tract of 205 
inoculated mice, tissue homogenates were prepared from individual lungs of mice culled at days 3, 6 206 
and 14 and titrated for infectivity in MDCK cells and for viral RNA by qPCR (Fig. 1F). WT and the CDLR 207 
mutant showed similar replication kinetics while there was marked replication deficit of CpG-high 208 
and UpA-high mutants, most evident at day 3 but remaining over 1 log below WT levels at day 6. For 209 
all mouse groups (WT, CDLR, UpA-high, CpG-high), IAV replication was undetectable by day 14, with 210 
all homogenates testing negative by virus isolation (Fig. 1F) and by qPCR (data not shown).   211 
 212 
Histopathology and innate host response to IAV infection. The histopathological changes associated 213 
with IAV infection in the lung were examined at three time points (days 3, 6 and 14 post-inoculation) 214 
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in mock infected mice and mice inoculated with 200pfu of WT, CDLR, CpG- and UpA-high variants of 215 
IAV. Histological examination revealed mild to marked, multifocal to coalescing, fibrinonecrotising 216 
bronchointerstitial pneumonia typical of IAV infection (Fig. 3A). Changes were consistent with an 217 
acute to subacute disease process at days 3 and 6 while day 14 samples exhibited more chronic 218 
pathology including prominent evidence of repair such as piling up of epithelial cells lining the 219 
airways and florid type II pneumocyte proliferation outlining alveolar spaces. Infection with the CpG-220 
high mutant virus produced less pathology at day 3 compared to the WT, CDLR and UpA-high 221 
variants. The CpG-high mutant also showed a significantly more rapid resolution of inflammation (Fig. 222 
3B; scored as the mean of perivascular, peribronchiolar and interstitial inflammatory lesions; p = 223 
0.01). Epithelial and interstitial necrosis was prominent in mice infected with all IAV variants, but had 224 
largely resolved by day 14 (Fig. 3C). Consistent with its reduced overall pathology, CpG-high showed 225 
more rapid resolution of epithelial and interstitial cell repair processes at day 14 (Figs. 3D; p = 0.01).  226 
Contrastingly, the histopathological changes in the UpA-high infected mice were similar to WT and 227 
CDLR infected mice at all time points and dosages. 228 
 229 
The induction of the major cytokines during acute infection with IAV was determined in pooled 230 
samples of lung homogenate from cohort groups at days 3, 6 and 14 after inoculation (Fig. 3; Figure 231 
Supplement 1). Substantial (>2-fold) induction of 21 of the 40 cytokines in the panel over levels in 232 
mock infected mice was observed in at least one IAV strain at days 3 and 6, but with these showed 233 
substantial variability in levels between time points. With the exception of IP-10, which was 234 
maximally induced at day 3, cytokine levels increased between days 3 and 6, while they became 235 
largely undetectable on day 14 after resolution of infection.  Most prominent among induced 236 
cytokines were chemokines (e.g. RANTES, MIP-1α) and less prominent induction of interleukins or 237 
TNF-α.  In contrast to the increased levels between days 3 and 6 in the majority of the inflammatory 238 
cytokines, individual mouse measurements of IFN-β mRNA by qPCR showed consistently higher 239 
levels at day 3, particularly in the WT and CDLR-infected groups (Fig. 3; Figure Supplement 2).  240 
Gaunt, Wise et al., eLife-12735 (Revised) 
Page 11 / 38 
Induction of cytokines was comparable in Experiment 1 on day 5 post-inoculation (Fig. 3; Figure 241 
Supplement 3). Differences were observed between WT and CDLR groups compared with the CpG-242 
high and UpA-high groups. WT (and CDLR) variants of IAV showed greater induction of cytokines on 243 
day 3 (BLC, I-TAC, JE, MIG, MIP-1α and 1β) while by day 6, responses were comparable to those of 244 
the clinically attenuated CpG-high- and UpA-high mutants.  MIP-1α was induced to substantially 245 
higher levels in mice infected with the latter viruses on day 6.  246 
 247 
Adaptive immune response to IAV infection. T cell responses to IAV infection at day 21 post-248 
inoculation were quantified using ICS and flow cytometry by measuring frequencies of ex vivo CD8+ 249 
and CD4+ T lymphocytes producing the cytokines IFN- γ, TNF-alpha or IL-2 upon exposure to pooled 250 
immunoreactive peptides in the NP (n=1) and HA (n=3) proteins. Lymphocytes extracted from lung 251 
(representing the local response) and spleen (systemic response) at day 21 post-infection were 252 
gated using the strategy outlined in Fig. 4; Figure Supplement 1. 253 
 254 
Infection of mice with IAV induced a strong IFN-γ response in the lungs of infected mice, with 255 
frequencies of antigen-specific CD8+ lymphocytes of at least 5% in WT and CDLR-inoculated mice 256 
(Fig. 4A, 4B). The population of IFN-γ producing CD8+ T cells in CpG-high mice was comparable 257 
(3.5%), while UpA infection induced a lower frequency of IFN-γ producing CD8+ T cells (1.2%). All 258 
variants of IAV induced comparable IFN-γ responses to IAV in CD8+ T lymphocytes recovered from 259 
the spleen with a 200 PFU inoculum (1.0-1.4%; Fig. 4B). These lymphocytes also showed induction of 260 
the cytokine TNF-α and IL-2 that was comparable between WT and CDLR, CpG- and UpA-high IAV 261 
mutants.  262 
 263 
Likewise peptide-specific CD4+ T cell responses were generated in all groups infected with variant or 264 
wild-type IAVs, directed at the single HLA Class II-restricted epitope included in the peptide cocktail. 265 
Overall the CD4+ T lymphocyte peptide-specific response recorded both locally (lung) and 266 
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systemically (spleen) was substantially weaker (< 0.5%) than that of CD8+ T cells (data not shown). In 267 
order to determine if infection by the attenuated viruses had effects on the hierarchy or magnitude 268 
of the T cell response to individual epitopes, ELISPOT assays were performed on thawed frozen 269 
splenocytes from mice infected with 200 PFU to quantify their responses against individual peptides 270 
used in the ICS cocktail (Fig. 4; Figure Supplement 2). Despite alterations to the NP coding sequence, 271 
the CpG-high, UpA-high and CDLR groups generated memory CD8+ T cell responses to the dominant 272 
NP epitope of equivalent magnitude to the wild-type infected animals.  CD8+ and CD4+ cell 273 
responses to the unaltered HA protein were unchanged and infection by the attenuated viruses did 274 
not appear to alter the hierarchy of dominant epitopes in the peptides measured.   275 
 276 
Induction of neutralising antibody to the PR8 strain of IAV was measured at days 6 and 21 post 277 
inoculation (Fig. 4B). High titres of antibody were induced at day 21 with comparable end point tires 278 
observed between WT / CDLR and the attenuated CpG and UpA-high IAV mutants at both measured 279 
time points.  280 
 281 
Immunoreactivity of CpG- and UpA-high mutants. To investigate the extent to which infection dose 282 
influenced host response, cohorts of 6 mice were infected with 20 PFU of IAV WT, CDLR, CpG-high 283 
and UpA-high IAV strains. Mice showed minimal weight loss and clinical signs over the infection 284 
period (data not shown) and consistent 10- to 100-fold reduction in lung viral loads as determined 285 
by infectivity and quantitative PCR measurements (Fig. 1F). This was associated with reduced 286 
pathology changes in the lung, with consistent reductions in mean scores for epithelial damage and 287 
inflammatory cell infiltrates across all variants of IAV (Fig. 3B, 3C). Significant differences were 288 
observed in the severity of pathology between CpG-high and control mice (WT and CDLR groups). 289 
The percentage of peptide specific CD8+ and CD4+ T cell responses in the mice given 10-fold lower 290 
doses (20 PFU) was correspondingly reduced in all the groups, with an approximately 5-fold 291 
reduction in local (lung) memory responses and a 3-fold reduction in the central (splenic) memory 292 
Gaunt, Wise et al., eLife-12735 (Revised) 
Page 13 / 38 
compartment as measured by IFN-γ production (Fig. 4B, 4C). Nonetheless, it is notable that even at 293 
the low dose all the modified IAV strains were able to generate T cell memory responses of 294 
comparable magnitude to that observed in the wild-type IAV-infected mice.  Induction of 295 
neutralising antibody, in contrast, was only minimally reduced in mice infected with 20 PFU 296 
compared to the original inoculating dose (Fig. 4B, 4C).  297 
 298 
Overall, with the exception of neutralising antibody induction, there was a strong dose dependence 299 
on all measured metrics of outcomes and host responses to IAV infection. These findings contrast 300 
markedly with the maintained immunoreactivity of CpG- and UpA-high mutants of IAV; despite their 301 
impaired replication in vivo (Fig. 1F), they maintained comparable innate and T cell responses to 302 
infection.   303 
 304 
Use of attenuated IAV variants as vaccines. Mice infected with the original 200 PFU dose of the 305 
CpG-high mutant showed an almost entirely non-pathogenic course of infection (absent clinical signs, 306 
4% weight loss), 10-100 fold lower viral loads (Fig. 1F) and reduced lung pathology (Fig. 3) and yet 307 
induced substantial host responses, equal to or greater in intensity to those of WT virus (4). This 308 
raised the question of whether the response to infection with the CpG high mutant conferred 309 
protection from re-infection. To investigate this and to determine the dose of virus required to 310 
confer protection, cohorts of 4 mice were infected with reduced doses (100, 50 and 20 PFU) of the 311 
CpG-high virus mutant and weight loss was compared with those infected at the original dose 312 
(Experiment 3 - Fig. 2C). Infection with the 200 PFU dose reproduced the minimal weight loss 313 
observed previously at day 6 (97.7% ± 0.4% of starting weight compared to 96.4% ± 2.7% previously 314 
observed (Fig. 2A, 2B)), while mice infected with all lower doses showed no significant weight loss 315 
relative to the uninfected control group. No mice showed clinical signs of infection.  316 
 317 
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At day 21 post-inoculation, mice in each group (200 PFU, 100 PFU, 50 PFU, 20 PFU and mock) were 318 
challenged with 200 PFU of PR8 WT virus. As expected, the mock-immunised group developed 319 
severe symptoms of infection comparable to the outcome of WT infection observed in previous 320 
experiments (Fig. 3D). In contrast, none of the mice previously inoculated with any dose of CpG-high 321 
virus showed clinical symptoms of infection or weight loss. Lung samples collected at day 6 post-WT 322 
inoculation with all doses of CpG-high IAV were consistently virus and PCR-negative, indicating that 323 
sterilising immunity had been achieved.  324 
 325 
 326 
DISCUSSION 327 
 328 
Increasing the frequencies of CpG and UpA dinucleotides in segment 5 of the PR8 strain transformed 329 
the phenotype of IAV in cell culture and in vivo. CpG- and UpA-high variants were attenuated in vitro 330 
and showed major alterations in pathogenicity on mouse inoculation. The approximately ten-fold 331 
reduction in replication kinetics reproduced the attenuation achieved in different classes of viruses 332 
where similar degrees of mutagenesis had been applied (see Table 1 in (17)), suggesting that 333 
attenuation originates through a shared, although as yet immunologically uncharacterised 334 
mechanism.  Quantitation of virion protein expression and production and of RNA copies from 335 
different IAV segments in viral stocks of WT and CDLR, CpG- and UpA-high mutants provided 336 
evidence that the mutated segment 5 viral RNA and protein were packaged appropriately  (Fig. 1, 337 
Figure Supplements 3, 4 and 5).  338 
 339 
The similarity in replication kinetics between WT and the permuted control, CDLR furthermore 340 
indicated that the attenuated phenotype of the CpG- and UpA-high mutants originated from 341 
compositional alterations in the coding sequence and was not the result of impaired translation  (24-342 
29), unintended disruption of uncharacterised RNA structure or replication elements embedded in 343 
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the segment 5 coding sequence. Segment 5 is indeed not suspected of coding for additional proteins 344 
in alternative reading frames and shows little evidence of RNA structure or other elements in the 345 
central coding region that are required for replication ((20, 21, 30, 31); Fig. 1, Figure Supplement 1). 346 
The mutagenesis applied left codon pair bias relatively unchanged (CPS of -0.011 compared to a WT 347 
score of 0.011; Table 1). Use of the permuted control, maintenance of the CPS score in mutants, 348 
verification of unimpaired transcriptional and translational profiles in virus stocks and application of 349 
mutagenesis in a region without alternative transcript production provides a sufficiently robust 350 
framework for us to be confident that the observed attenuation of the CpG- and UpA-high viruses 351 
was primarily the result of the introduction of CpG and UpA dinucleotides. 352 
 353 
Development of an attenuated vaccine for influenza A virus. The CpG-high virus was replication 354 
defective and infections in mice were associated with a clear reduction in pathogenicity compared to 355 
WT and oterIAV mutants. However, the CpG-high mutants induced comparable immune and 356 
cytokine responses to WT virus, including potent T cell responses both in the lung and spleen (Fig. 357 
4B), equivalent to the response to WT virus despite its >10-fold reduction in replication. In contrast, 358 
the UpA-high virus also showed restricted replication yet infections in mice were accompanied by 359 
substantial pathogenicity, including weight loss, clinical signs of infection and inflammatory / 360 
necrotic damage to the lung comparable to WT virus.    361 
 362 
Several attributes of the CpG-high mutant produced in the current study are therefore favourable 363 
for the potential future use of this attenuation strategy to produce an effective and safe vaccine for 364 
IAV. Firstly, we have documented that its attenuated phenotype results directly from the 365 
compositional changes in segment 5 since other forms of sequence disruption that retained 366 
dinucleotide frequencies (CDLR) was phenotypically equivalent to WT. Thus attenuation is based on 367 
the cumulative effect of several hundred individual nucleotide changes associated with increasing 368 
CpG and UpA dinucleotide frequencies that cannot readily revert to wild type virulence. This 369 
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contrasts with conventional attenuation mechanisms, in which replication ability is decreased 370 
through the presence of a limited number of nucleotide changes that may potentially revert. For 371 
example, attenuation of the currently used temperature sensitive FluMist backbone of IAV is 372 
dependent on only 4-5 amino acid changes (32) and there is at least the theoretical possibility that 373 
one or more of these may revert and increase virulence in vaccinees.  374 
 375 
As reviewed previously (33-35)., attenuated vaccines share with inactivated IAV vaccines an ability to  376 
induce powerful T cell responses that represent an important element of the protective immunity to 377 
wild type challenge. The CpG-mutant in the current study induced these responses both in the lung 378 
and spleen (Fig. 4B), equivalent to the response to WT virus despite its >10-fold reduction in 379 
replication in the lung. The presence of T cell epitopes in more conserved genome regions than HA 380 
and NA additionally provides the ability of a monovalent attenuated vaccine to confer protection 381 
against heterologous IAV challenge, as has been demonstrated in experimental mouse models (14, 382 
36).     383 
 384 
Finally, while both CpG- and UpA-high mutants showed replication impairment in cell culture and in 385 
vivo, the CpG-high mutant showed substantially greater attenuation of pathogenicity, despite the 386 
greater restriction of replication of UpA-high in vivo. These findings suggest the existence of 387 
additional host response factors and interactions beyond replication phenotype in determining 388 
outcomes of infection. These may potentially be related to the ability of both CpG- and UpA-high 389 
mutants to induce powerful innate and adaptive immune responses in infected mice 390 
disproportionate to their replication phenotypes. The key observation was the equivalence in T cell 391 
and B cell responses and induction of local cytokine responses by virus mutants that replicated 10-392 
100 fold less in the lung than WT (or CDLR) viruses. Contrastingly, inoculation of all of these viruses 393 
at a ten-fold lower dose reduced host response to a degree comparable to their reduction in 394 
replication. Similar maintenance of host response despite attenuation of replication has been 395 
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observed repeatedly in other studies in which codon or codon pair usage was altered (13, 14, 24). As 396 
discussed above, these parallel outcomes would be anticipated if their replication impairment arose 397 
though unintended increases in CpG and UpA frequencies. Contrastingly, observations of their 398 
apparently enhanced immunogenicity would furthermore be highly problematic to explain had their 399 
attenuation been dependent purely on inhibition of replication through retardation of translation.  400 
 401 
Understanding the pathways by which CpG- and UpA-high virus mutants are attenuated is essential 402 
before dinucleotide compositional alteration can be adopted as generic vaccine strategy. As 403 
discussed previously (29), attenuation is dependent more on an active restriction pathway within the 404 
cell rather than CpG- and UpA-high mutants being intrinsically defective. In the future development 405 
of CpG-high mutants as attenuated vaccines, further work is clearly required to understand how this 406 
compositional change can uncouple the three outcomes of replication kinetics, host immune 407 
response and pathogenicity. The apparent “adjuvanting” effect of increased CpG and UpA 408 
dinucleotides on host immune response observed in the current study is highly relevant to the 409 
balance between vaccine efficacy and safety. Documenting the pathway(s) by which the cellular 410 
restriction of replication observed in cell culture (18, 37) mediates the enhanced inflammatory and 411 
adaptive immune responses observed in vivo is important in understanding this phenomenon.  412 
 413 
 414 
MATERIALS AND METHODS 415 
 416 
Cell culture and cell lines . Human embryonic kidney (293T) cells, human alveolar basal epithelial 417 
(A549) cells and Madin-Darby canine kidney (MDCK) cells were cultured in Dulbecco’s modified 418 
Eagle's medium (DMEM) supplemented with 10% foetal bovine serum (FBS), penicillin (100 U/ml) 419 
and streptomycin (100 μg/ml). All cells were maintained at 37oC with 5% CO2.  All three cells were 420 
tested at 3-6 month intervals for mycoplasma contamination by a commercial PCR-based method 421 
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and found negative. The identity of A549 and MDCK cells was verified by their sialic acid repertoires 422 
and at the species level by their differential sensitivity to human β-interferon.  Cell lines were 423 
originally provided by the National Institute for Medical Research, Mill Hill, London, UK.  424 
 425 
 426 
In silico construction of mutants with modified segment 5 sequences. The MDCK-adapted PR8 427 
laboratory strain cloned by de Wit and colleagues (19) was used as the reference genome in the 428 
construction of all mutants. CpG and UpA frequencies were separately maximised between positions 429 
151 and 1514 in segment 5 (NP) of the PR8 strain (Genbank accession number EF467822) while 430 
preserving coding using the Program Sequence Mutate in the SSE package (22) (Table S1). As a 431 
control, a permuted mutant was designed using the program CDLR in the SSE package that 432 
scrambles the order of codons encoding the same amino acids but preserves dinucleotide 433 
frequencies, codon usage and encoded amino acid sequence. DNA constructs of the designed 434 
sequences were synthesised (GeneArt; sequences listed in the Supplementary Data file). For all 435 
sequences, ratios of observed CpG and UpA frequencies to expected frequencies derived from 436 
mononucleotide composition were calculated by the formula f(XpY)/f(X)*f(Y) and referred to as O/E 437 
ratios (Table 1). The codon adaptation index for human codon usage was calculated through the 438 
website http://genomes.urv.es/CAIcal/ (38). 439 
 440 
Recovery of mutant IAVs. IAV particles were generated using reverse genetic approach as described 441 
previously (39). Firstly, sequences of the mutated segment 5 sequences were assembled into 442 
separate bidirectional expression (“pDUAL”) plasmids. Then, 8 pDUAL plasmids (250 ng each with 4μl 443 
Lipofectamine 2000 (Life Technologies) containing sequences of a complete IAV genome were used 444 
to transfect 293T cells simultaneously, with transfections either incorporating the WT segment 5 445 
sequence or a dinucleotide modified version. After overnight incubation, virus growth medium 446 
(DMEM supplemented with 5 μg/ml TPCK-treated trypsin, 0.14% BSA fraction V and penicillin (100 447 
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U/ml) and streptomycin (100 μg/ml)) was added to allow a small-scale amplification of the viruses in 448 
293T cells. After 48 hours, the virus particle-containing supernatants were passaged on MDCK cells 449 
or in embryonated chicken eggs to further amplify the viruses to obtain working stocks. To confirm 450 
the sequences of recovered IAV mutants were correct, RNA was extracted from the virus-containing 451 
supernatants using QIAamp Viral RNA Mini Kits (Qiagen). A reverse transcription reaction was 452 
performed using SuperScript II Reverse Transcriptase (Life Technologies).  Subsequently, the cDNA 453 
was amplified by polymerase chain reaction (PCR) using segment 5-specific primes listed in Table 2, 454 
and sequenced by BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies).  455 
 456 
Infectivity titrations. Virus titres were determined by plaque titration using 10-fold serial dilutions of 457 
virus stocks. Confluent MDCK cells in 6 well plates were inoculated with virus stock for 1 hour, then 458 
an overlay (mixture of equal volume of DMEM and 2.4% Avicel (Sigma-Aldrich) supplemented with 1 459 
µg/ml TPCK-treated trypsin and 0.14% BSA fraction V) was put onto the wells. After 48 hours, cells 460 
were fixed using 3.5% formaldehyde and stained with 0.1% crystal violet. Virus titres were calculated 461 
by plaque count*dilution factor/(volume of inoculum) and expressed as PFU/ml. Plaque sizes were 462 
quantified by ImageJ software. HA assays were performed as previously described (39). To analyse 463 
virion composition, clarified allantoic fluid was pelleted through a 33% sucrose pad at 91,000 g as 464 
previously described (39). 465 
 466 
Reverse transcription quantitative polymerase chain reaction (RT-qPCR). For quantification of vRNA 467 
in culture supernatants, RNA was extracted from viral supernatants using QIAamp Viral RNA Mini 468 
Kits (Qiagen). DNA was removed by either RNase-Free DNase Set (Qiagen) or RQ1 RNase-Free DNase 469 
(Promega). Reverse transcription quantitative polymerase chain reactions (RT-qPCR) were carried 470 
out using Bioline SensiFAST one-step RT-PCR kit (BIO-82020) with modified cycling conditions – 45°C 471 
for ten minutes, 95°C for 2 minutes, then 40 cycles of 95°C for 10s, then 60°C for 30s using segment 472 
1 and 5 primers listed in Table 2).  473 
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 474 
Replication phenotype in vitro. MDCK cells were infected in triplicate with WT virus and the mutants 475 
at a multiplicity of infection (MOI) of 0.01 (multi-step replication cycle) or 1 (single replication cycle). 476 
The supernatants were harvested at multiple time points (12, 24, 48 hours post-infection). Viral 477 
titres were similarly determined at 24 hours using 5 replicate cultures. RNA / infectivity ratios were 478 
determined by determining RNA amount in viral supernatants by qPCR using primers from segment 479 
5 and comparing this with their infectivity titres.  480 
 481 
Plating efficiency. A549 cells were infected at an empirically determined MOI (by titration) that gave 482 
~10 % levels of infection for 6 hours, after which cells were fixed, permeablised and stained for a 483 
range of viral proteins. M2 was detected by ab5416 (Abcam), NS1 by an in-house (rabbit) antiserum, 484 
NA by an in house (mouse) antiserum, NP by ab20343 (Abcam) and PB2 by an in house rabbit 485 
antiserum. Secondary antibodies were species specific Alexafluor-488 or Alexafluor-546 (A21202, 486 
A11005, A21207 and A21206, Life Technologies). 487 
 488 
Amplification of IAV stocks in embryonated eggs. 200PFU of virus stocks were inoculated into 11 489 
day old chick eggs and incubated for 2 days. Eggs were chilled at 4°C overnight, then allantoic fluid 490 
was harvested, checked for virus by HA assay, and pooled as virus stock. Stocks were centrifuged and 491 
then ultracentrifuged at 48,000g for 90 minutes on a 30% sucrose cushion. Pellets were resuspended 492 
directly in laemmli buffer for SDS-PAGE and coomassie staining following standard protocols. 493 
 494 
Competition assays. To compare the relative replication fitness of WT virus and the mutants, equal 495 
titres of a pair of viruses were mixed as the “starting inoculum” to infect A549 cells simultaneously. 496 
Following development of a cytopathic effect (CPE), the supernatant was diluted by 100 fold and 497 
used to inoculate fresh A549 cells for the next passage. After 5 or 10 passages, the supernatant was 498 
withdrawn for RNA extraction and reverse transcription. A specific region on Segment 5 was 499 
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amplified by a primer pair that anneals equally to the 2 mutants (Table 2). The amplicons were then 500 
treated with restriction enzymes that only digest one of the 2 amplicons (Table 3). Similar 501 
procedures were also performed on the starting inoculum. The digested PCR products were 502 
separated by electrophoresis. The ratios of digested and undigested bands were quantified and 503 
normalized by the ratio in the starting inoculum. 504 
 505 
Replication phenotype in vivo. This was assessed in the BALB/c mouse model. All animal 506 
experiments were carried out under the authority of a UK Home Office Project Licence (60/4479) 507 
within the terms and conditions of the strict regulations of the UK Home Office ‘Animals (scientific 508 
procedures) Act 1986’ and the Code of Practice for the housing and care of animals bred, supplied or 509 
used for scientific purposes. Groups of six 8 week-old female BALB/c mice were intranasally infected 510 
with between 20 and 200 PFU of influenza virus PR8 strain in 40 µl DMEM under oxygenated 511 
isofluorane anaesthesia. Mice were weighed daily and assessed for clinical signs of infection. At 512 
various time points post-inoculation, mice were euthanized and whole blood was collected with 513 
subsequent collection of plasma supernatant after coagulation (for microneutralisation assays). Left 514 
lungs were harvested for qPCR (as above), plaque assay (as above), mouse cytokine arrays (below) or 515 
T cell assays (below). The four lobes of the right lung were inflated with and then immersed in 10% 516 
neutral buffered formalin (Sigma Aldrich) until fixed, then processed using routine methods and 517 
embedded in paraffin blocks. 5μm thin section were cut and stained with haematoxylin and eosin for 518 
histological examination. The sections were assessed (blinded) by a veterinary pathologist (PMB).  519 
The individual pathology features assessed were damage to the airway epithelium (degeneration, 520 
necrosis and repair), perivascular inflammation, peribronchi/bronchiolar inflammation, interstitial 521 
inflammation, interstitial necrosis and type II pneumocyte hyperplasia. Each feature was scored from 522 
1 (mild) to 3 (marked). The percentage of lung affected was also noted.  A challenge experiment was 523 
undertaken, whereby mice in groups of 4 were inoculated with 100, 50, or 20 PFU of CpG-high virus, 524 
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or mock infected (DMEM only). At 3 weeks post-inoculation, mice were challenged with 200 PFU of 525 
WT PR8 virus. Mice were euthanised at 6 days post-challenge.  526 
 527 
Mouse cytokine array. Equal volume of homogenates of lungs in the same group was pooled 528 
together. Levels of cytokines were determined using Mouse Cytokine Antibody Array - Panel A (R&D 529 
systems ARY006) commercial kit according to its instruction. Briefly, cytokines in lung homogenates 530 
were detected by a detection antibody cocktail and subsequently attached to antibody spots printed 531 
on membranes with each spot recruiting one cytokine. A fluorescence dye was then added and 532 
fluorescence of each spot was visualised and quantified using LI-COR Odyssey Infrared Imaging 533 
System. For each cytokine, spots were printed in duplicate. An average value was calculated and 534 
normalized by the mock-infected control. A heat map was generated based on the folds of induction 535 
over the mock-infected group. Cytokines with >2 fold induction over mock-infected group and 536 
with >2 fold induction or inhibition compared with the WT-infected group were highlighted in a 537 
parallel heat map.  538 
 539 
Microneutralisation assay. Mouse sera were pre-treated with receptor destroying enzyme using the 540 
RDE Kit (Cosmos Biomedical) according to manufacturer’s instructions. Confluent MDCK cells in 96 541 
well plates were washed to remove FCS, and mouse sera were added to plates and 2-fold serially 542 
diluted down the plate to a final dilution of 1:1280. 200 PFU/ well of PR8 virus stock was added, and 543 
wells were overlaid 1:1 with Avicel containing trypsin and BSA as described previously. Cells were 544 
incubated at 37°C overnight. Overlay was removed and the cells were fixed with 3.5% 545 
paraformaldehyde and permeabilised with 0.2% Triton-X100. Primary antibody reactive for influenza 546 
A NP was added 1/1000 (Abcam, ab20343) in ELISA buffer (10% horse serum, 0.1% Tween-20) and 547 
incubated for 1 hour. Cells were washed and secondary antibody (peroxidase labelled anti-mouse 548 
antibody, Thermo scientific SA1-100) was added 1/1000 in ELISA buffer for 1 hour. Cells were 549 
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washed and treated with True Blue Peroxidase (KPL, 50-78-02) according to manufacturer’s 550 
instructions, and then visually inspected for colorimetric differences.  551 
 552 
Intracellular cytokine staining (ICS) and flow cytometry. Mice were euthanized at day 21 post-553 
inoculation and the lungs and spleen were removed for analysis. Single cell suspensions were 554 
generated from perfused lung by incubating the dissociated tissue in RPMI containing DNase and 555 
collagenase, and then passing the digested tissue through a 45 µm cell sieve to release the tissue-556 
bound lymphocytes. These were treated with ACK lysing buffer (Life Technologies) to remove red 557 
blood cells and then resuspended in RPMI+10% FCS. Spleens were dissociated through a 45µm cell 558 
sieve and then ACK lysing buffer was used to remove red blood cells. The splenocytes were 559 
resuspended in RPMI+10% FCS. Lung and spleen single cell suspensions were counted using an 560 
automated cell counter (Biorad). 106 splenocytes or lung lymphocytes were incubated for 6 hours at 561 
37°C with a cocktail of peptides (NP147-155 (TYQRTRALV), HA518-526 (IYSTVASSL), HA 462-472 (LYEKVKSQL) 562 
and HA 126-138 (HNTNGVTAACSHE) (ProImmune)) designed to activate both CD8+ and CD4+ influenza 563 
PR8-specific T cells. Media-only wells were included as negative controls. Golgi-stop was added 2 564 
hours post-stimulation and stimulation was stopped by storing the cells at 4°C 4 hours later. ICS was 565 
performed according to methods provided with the Cytofix/Cytoperm kit (BD Bioscience). Briefly, 566 
the cells were treated with Fc block (eBiosciences) and then labelled with Fixable Near-IR Dead Cell 567 
Stain Kit (Life Technologies) and the fluorochrome conjugated monoclonal antibodies CD8-568 
PerCPCy5.5 (eBioscience) and CD4-eFluor450 (eBioscience), followed by fixation and 569 
permeabilisation. The anti-cytokine antibodies IFN-γ-APC (eBiosciences), TNF--FITC (eBiosciences) 570 
and IL-2-PE (BD Bioscience) were added, and then cells were washed and resuspended in FACS 571 
buffer (PBS, 2% FCS, 0.1% NaN3, 5 mM EDTA). Samples were analyzed on the LSRII flow cytometer 572 
(BD Biosciences).  573 
 574 
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IFN-γ ELISpot Assay. IAV peptides were selected to match the sequence of the PR8 strain of IAV and 575 
to represent immunodominant epitopes in the BALB/c strain (Influenza Research Database, 576 
http://www.fludb.org). CD8+ T cells from BALB/c mice respond strongly to an epitope in the NP 577 
protein NP147-155 (TYQRTRALV) (NP) and two further epitopes in the HA protein, HA518-526 (IYSTVASSL) 578 
(HA-dom) which is dominant and HA462-472 (LYEKVKSQL) (HA-sub) which induces weaker responses. 579 
The HA protein also contains a CD4+ T cell epitope HA126-138 (HNTNGVTAACSHE) (HA-CD4), which was 580 
measured in these experiments.  581 
 582 
IFN-γ ELISpot assays were performed on frozen splenocytes thawed and rested overnight in 3ml 583 
RPMI+10% FCS (R10) in 37°C, 5% CO2. Assays were performed according to the manufacturer’s 584 
instructions (Mabtech). Briefly, rested splenocytes were plated in duplicate at a concentration of 1-2 585 
× 105 splenocytes per well in Hydrophobic Immobilon Membrane plates (Merck Millipore) coated 586 
with 100µl of anti-IFN-γ (10µg/ml) (Mabtech). Cells were stimulated with the individual peptides 587 
(3µg/ml final concentration) which constituted the peptide cocktail used in the ICS. Cells were 588 
stimulated with R10+0.1% DMSO as negative control. After overnight stimulation at 37°C, 5% CO2, 589 
the wells were washed and the number of IFN-γ producing cells detected by addition of biotinylated 590 
anti-IFN-γ (Mabtech) (50µl at 1µg/ml), followed by Streptavidin-AP (Vectorlabs) (50µl at 1:750 591 
dilution) and the substrate NBT/BCIP (Thermo Fisher). The number of spots generated in each well 592 
was counted using an automated ELISPOT reader (AID Elispot). The number of spots generated in the 593 
negative control wells was used to determine the limit of detection of the assay (5 spots per 106 594 
cells).   595 
 596 
597 
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FIGURE LEGENDS 703 
 704 
Fig. 1. Replication phenotypes of IAV WT and compositionally altered mutants.  705 
 706 
(A) Replication kinetics of IAV in a multi-cycle replication assay; MDCK cells were infected at an MOI 707 
of 0.01 and supernatant assayed for IAV RNA at three post-infection time points; y-axis records 708 
infectivity of supernatant on titration in MDCK cells. Error bars show SEM of 3 replicate assays. A 709 
single replication cycle assay is shown in Figure Supplement 1 710 
 711 
(B) Infectivity titres of supernatants collected at 24 hours. Bars show geometric titres of 5 replicate 712 
cultures of WT, CDLR, CpG-high and UpA-high variants; error bars show SEMs. The significance of 713 
titres differences was determined by Kruskall-Wallis non-parametric test; p values shown above bars 714 
with significant values highlighted in bold  715 
 716 
(C) Mean plaque diameters of approximately 30 plaques of WT and mutant IAV variants; error bars 717 
show SEMs.  718 
 719 
(D, E) HA and RNA / infectivity ratios of WT and permuted, CpG-high and UpA-high mutants in MDCK 720 
cells; bar heights show mean values from 2-3 replicate assays; error bars show standard errors of the 721 
mean (SEM).  722 
 723 
(F) Infectivity titres of lung homogenates collected at days 3, 6 and 14 (experiment 2; Fig. 2) and day 724 
7 from mice infected with 20 PFU (experiment 3) from inoculated mice determined by titration on 725 
MDCK cells. Bar heights show mean values from cohorts of 4-6 mice; error bars show SEM 726 
 727 
Synonymous site variability and composition analysis of IAV segment 5 is shown in Figure 728 
Supplement 1.  729 
Replication kinetics of IAV in a single cycle / high MOI replication assay is shown in Figure 730 
Supplement 2.  731 
Expression of IAV viral proteins M2, NS1, NA and PB2 relative to that of NP in different IAV mutants 732 
at 6 hours post-infection is shown in Figure Supplement 3 733 
 734 
Detection of IAV viral proteins HA1, M1 and HA2 relative to that of NP in purified virions from 735 
different IAV mutants is shown in Figure Supplement 4 736 
Ratio of segment 5 and segment 2 RNA sequences in purified virions is shown in Figure Supplement 737 
5 738 
Pairwise comparisons of the replication fitness of the mutants by competition assays is shown in 739 
Figure Supplement 6 740 
 741 
 742 
Fig. 2. Infection outcomes and protective immunity in mice infected with IAV. 743 
 744 
(A, B) Weights of mice (proportion of starting weight) of mice inoculated with 200 PFU of IAV WT 745 
and mutant strains with altered dinucleotide compositions. Deaths of individual mice are shown 746 
underneath the x-axis using the same colour coding. (C) Weight loss of mice infected with different 747 
inoculum doses (20 - 200 PFU) of the CpG-high IAV mutant (D) weight loss in the mice previously 748 
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infected with CpG-high IAV (in Fig. 2C) with a 200 PFU WT challenge dose at day 21 after the original 749 
inoculation. In all graphs, error bars show SEMs of 4-6 mice per group. 750 
 751 
Fig. 3. Cytopathology and innate immune responses to IAV infection in mice 752 
 753 
(A) Representative lung sections from mice infected with WT (a, b, e, f) and CpG-high (c, d, g, h) IAV 754 
variants at days 3 (a-d) and 14 (e-h) post infection. At day 3 prominent peribronchiolar and 755 
perivascular accumulation of inflammatory cells are present in WT infected mice (a), with moderate 756 
to marked, multifocal to coalescing airway epithelial cell necrosis (b). The inflammatory and necrotic 757 
lesions in this acute phase of disease are less severe in the CpG-high infected mice (c, d). At day 14 758 
WT-infected mice showed marked peribronchial and perivascular lymphohistiocytic inflammation (e), 759 
epithelial regeneration and prominent type II pneumocyte proliferation (f). Again, the lesions in the 760 
CpG-high infected mice during this repair stage of disease were less severe (g, h). Bars in figures a, c, 761 
e, and g represent 200µm. Bars in figure b, d, f, and h represent 20µm. 762 
 763 
(B, C and D) Blinded histological scoring of (B) inflammation, (C) necrosis, and (D) repair processes in 764 
sections of lung from mice infected with different IAV strains. Bar heights show mean values from 4-765 
6 mice per group scored from 0-3 for severity of (B) inflammation (perivascular, peribronchiolar and 766 
interstitial), (C) epithelial and interstitial necrosis, and (D) epithelial cell repair and type II 767 
pneumocyte proliferation. All average scores were normalised by the area of lung affected in the 768 
section. The significance of differences in pathology severity between viruses was determined by 769 
Kruskall-Wallis non-parametric test (combining WT and CDLR scores); p values shown above bars 770 
with significant values highlighted in bold. Error bars show SEM.  771 
 772 
Induction of individual cytokine in mice infected with IAV infection at different time point post-773 
inoculation is shown in Figure Supplements 1 and 3 774 
 775 
Induction of interferon-β mRNA in lung samples is shown in Figure Supplement 2  776 
 777 
 778 
Fig. 4. Adaptive immune response (T cell and neutralising antibody) after infection with wild-type 779 
and mutant strains of IAV 780 
 781 
A) Representative FACS plots showing the percentage of IFN-γ producing cells in mice infected with 782 
200 PFU of IAV in the CD8+ T cell population after peptide stimulation.  783 
 784 
(B, C) Mean frequencies of CD8+ T lymphocytes expressing IFN- γ, TNF-α or IL-2 from spleen and lung 785 
at day 21 and neutralising antibody titres at days 6 and 21 post-infection with 200 PFU or 20 PFU of 786 
IAV respectively. Bars show mean frequencies of lymphocyte subsets and antibody titres from 4-6 787 
mice per group; error bars show SEM.  788 
 789 
The gating strategy to identify CD8 lymphocytes is shown in Figure Supplement 1.  790 
 791 
Reactivity to individual peptides is shown in Figure Supplement 2. 792 
793 
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TABLE 1 794 
 795 
COMPOSITION AND CODING PARAMETERS OF THE MUTATED REGION OF SEGMENT 5 796 
 797 
 798 
 Subs.a C+G% CpG ΔCpG 
b 
CpG-O/E 
c
 
UpA ΔUpA 
b 
UpA-O/E CAI CPS d 
PR8 WT --- 0.46 28 --- 0.43 43 --- 0.49 0.745 0.005 
CDLR 134 0.46 28 0 0.43 43 0 0.49 0.745 0.011 
CpG-high 233 0.46 114 +86 1.63 45 +2 0.51 0.611 -0.011 
UpA-high 199 0.46 29 +1 0.56 116 +73 1.31 0.627 -0.118 
 799 
a Number of sequence changes from WT sequence 800 
b Change in the numbers of CpG and UpA dinucleotides 801 
c Observed to expected frequencies of CpG and UpA dinucleotides 802 
dCalculated as previously described  (40) 803 
 804 
805 
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TABLE 2 806 
 807 
Primers used for qPCR and for amplification of segment 5 for competition assays 808 
 809 
Gene/Region Aim Primer type Sequence 
Seg 5 Reverse Transcription Sense ATCATGGCGTCTCAAGGCAC 
Seg 5 Sequencing Sense GAATGCCACTGAAATCAGAG 
Antisense CGTCCGAGAGCTCGAAGACT 
Seg 5 Competition Assay Sense CCAGAATGCCACTGAAATCA 
Antisense CCTTGCATYAGMGAGCACAT 
Seg 5 RT-qPCR Sense ATCATGGCGTCTCAAGGCAC 
Antisense CCGACGGATGCTCTGATTTC 
GAPDH RT-qPCR Sense CTACCCCCAATGTGTCCGTCG 
Antisense GATGCCTGCTTCACCACCTTC 
IFN-β RT-qPCR Sense CACAGCCCTCTCCATCAACT 
 Antisense GCATCTTCTCCGTCATCTCC 
 810 
811 
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TABLE 3 812 
List of enzymes used in pairwise competition assays 813 
 814 
Virus 1* Virus 2* Restriction Enzyme Digestion Site 
WT Permuted Hpy188III In Permuted 
WT CpGH Hpy188III In CpGH 
WT UpAH Hpy188III In UpAH 
CpGH UpAH AhdI In CpGH 
CpGH Permuted AhdI In CpGH 
UpAH Permuted BsaHI In UpAH 
 815 
*Virus pairs to be differentiated 816 
817 
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SUPPLEMENTARY DATA 818 
 819 
Sequences of the mutated regions in segment 5 of IAV (CDLR, CpG-high and UpA-high) are provided 820 
in the Supplementary File.  821 
 822 
823 
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FIGURE SUPPLEMENTS 824 
 825 
 826 
Fig. 1, Figure Supplement 1. Variability and composition analysis of IAV segment 5 827 
 828 
(A) Variability at synonymous sites of selected subtypes of IAV (H1N1, H3N2, avian-derived variants 829 
H5, H6 and H9) in the coding region of segment 5 recorded as mean within-group pairwise p-830 
distance. Sequences were scanned using window size of 30 codons, incrementing by 2 codons. (B) 831 
CpG and UpA dinucleotide frequencies in the coding region of segment 5, using mean values of 120 832 
bases incrementing by 1 base per data point.  833 
 834 
Fig. 1, Figure Supplement 2. Single replication cycle kinetics of IAV infected an am MOI of 5 835 
Replication kinetics of IAV in a single-cycle replication assay; MDCK cells were infected at an MOI of 836 
5 and supernatant assayed for IAV RNA at 5 post-infection time points; y-axis records infectivity of 837 
supernatant on titration in MDCK cells. 838 
 839 
Fig. 1, Figure Supplement 3. Expression of IAV viral proteins M2, NS1, NA and PB2 relative to that of 840 
NP in different IAV mutants 841 
 842 
Frequency of MDCK cells expressing different viral proteins 6 hours after infection with WT and 843 
mitant strains of IAV. Frequencies of infected cells were compared to those expressing the NP 844 
protein encoded by segment 5.   845 
 846 
Fig. 1, Figure Supplement 4. Detection of IAV viral proteins HA1, M1 and HA2 relative to that of NP 847 
in purified virions of different IAV mutants 848 
 849 
(A) PAGE of purified IAV virions derived from egg cultures of WT and mutant IAV strains. The major 850 
contaminant band in the CDLR preparation is most likely ovalbumin; its presence did not influence 851 
our ability to quantify IAV protein. (B) Viral proteins were quantified by densitometry and amounts 852 
relative to that of the NP protein (encoded by segment 5) plotted on y-axis.   853 
 854 
Fig. 1, Figure Supplement 5. Ratio of segment 5 and segment 2 RNA sequences in purified virions 855 
Quantitation of segment 5 and segment 2 RNA by qPCR in purified virions of WT and mutant IAV 856 
strains. The y-axis records mean values of two biological replicates with values normalised to the 857 
ratio observed in WT virus; error bars show SEMs.  858 
 859 
Fig. 1, Figure Supplement 6. Pairwise comparisons of the replication fitness of the mutants by 860 
competition assays 861 
 862 
(A) Assay design and relative quantitation of virus pairs using restriction enzyme digestion of PCR 863 
product to differentiate amplicon sequences. (B) Summary results of pairwise comparisons. Cells 864 
were filled to illustrate diagrammatically the frequency of variants listed in columns; values and 865 
passage numbers indicated in boxes. The relative fitness ranking was PR8-WT ≥ CDLR >> UpA-high = 866 
CpG-high. 867 
 868 
Fig. 3, Figure Supplement 1. Cytokine response to IAV infection at different time point post-869 
inoculation 870 
 871 
Induction of individual cytokines in pooled lung samples (n=6) collected at days 3, 6 and 14 post-872 
inoculation. The y-axis records fold-induction over cytokine level detected in uninfected mice; only 873 
cytokines showing significant (> 2 fold induction at any time point) are shown on the graph; no 874 
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induction of the following cytokines were recorded: C5/C5a, Eotaxin, I-309, IL-10, IL-12 p70, IL-13, IL-875 
16, IL-1α, IL-2, IL-23, IL-27, IL-3, IL-5, M-CSF, SDF-1, sICAM-1, TARC and TNF-α.    876 
 877 
Fig. 3, Figure Supplement 2. Induction of interferon-β mRNA in lung samples 878 
 879 
Quantitation of IFN-β mRNA in lungs of infected mice at days 3 and 6 by qPCR. Bars record mean 880 
levels; error bars show SEM. IFN-β was undetectable in all lung samples collected at day 14 (data not 881 
shown).  882 
 883 
Fig. 3, Figure Supplement 3. Cytokine responses in lungs of mice infected in experiment 1 (day 5) 884 
 885 
Induction of individual cytokines using a standard mouse panel in pooled lung samples (n=6) 886 
collected at days 3, 6 and 14 post-inoculation. The y-axis records fold-induction over cytokine level 887 
detected in uninfected mice; only cytokines showing significant (> 2 fold induction at any time point 888 
are shown on the graph; no induction of the following cytokines were recorded: C5/C5a, Eotaxin, I-889 
309, IL-10, IL-12 p70, IL-13, IL-16, IL-1α, IL-2, IL-23, IL-27, IL-3, IL-5, M-CSF, SDF-1, sICAM-1, TARC and 890 
TNF-α.  891 
 892 
Fig. 4, Figure Supplement 1. Gating strategy to identify and quantify lymphocytes producing IFN-γ 893 
 894 
Gating strategy used to isolate the population of CD8 T cell IFN-γ producers after peptide stimulation 895 
 896 
Fig. 4, Figure Supplement 2. ELISPOT analysis of T cell reactivity to individual IAV peptides.  897 
 898 
The number of IFN-γ reactive SFU per 106 measured using ELISPOT following overnight stimulation of 899 
thawed splenocytes with peptides or media from mice immunised 21 days earlier with 200pfu of the 900 
indicated viruses. Bars show mean frequencies of lymphocyte subsets from 3-4 mice per group. Error 901 
bars show standard deviation. 902 




